MAX-40279-01 + azacitidine

MAX-40279-01 + azacitidine is an investigational combination therapy for hematologic malignancies, notably acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), combining MAX-40279-01—a multi-target, orally bioavailable small molecule inhibitor of FLT3, FGFR, HPK1, JAK, PDGFR, and VEGFR developed by Maxinovel Pharmaceuticals—with azacitidine, a hypomethylating agent targeting DNA methyltransferases. MAX-40279-01 is designed to overcome resistance seen with current FLT3 inhibitors by also antagonizing FGFR and related tyrosine kinases, key drivers in leukemogenesis and resistance pathways. Azacitidine is an established standard-of-care for AML and MDS, working by incorporating into DNA and RNA to inhibit DNA methyltransferase, thereby causing hypomethylation of DNA and direct cytotoxicity to abnormal hematopoietic cells. The combination aims to provide synergistic antileukemic effects through dual targeting of kinase-driven survival pathways and epigenetic modulation[1][2][3][5][7][8].